Amicus Therapeutics (Nasdaq: FOLD) is a global, patient-centric biotechnology company focused on discovering, developing and delivering novel high-quality medicines for people living with rare metabolic diseases. The cornerstone of the Amicus portfolio is Galafold, an oral precision medicine for people living with Fabry disease who have amenable GLA variants. The lead biologics program in the Amicus Therapeutics pipeline is AT-GAA, an investigational therapy for Pompe disease. Amicus Therapeutics is committed to advancing and expanding a robust pipeline of cutting-edge, first- or best-in-class medicines for rare metabolic diseases. Source
No articles found.
We are a global frontrunner in making oral vaccines a reality. Weâve created a p...
We are a global frontrunner in making oral vacc...
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) is a global biopharmaceutical company that...
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) is a gl...
Headquartered in Nashville, Tennessee, Surgery Partners is a leading healthcare se...
Headquartered in Nashville, Tennessee, Surgery ...
Provention Bio, Inc. is a clinical-stage biopharmaceutical company developing nove...
Provention Bio, Inc. is a clinical-stage biopha...
Sutro Biopharma, located in South San Francisco, is a clinical-stage drug discover...
Sutro Biopharma, located in South San Francisco...
MediciNova, Inc. is a publicly-traded biopharmaceutical company focused on acquiri...
MediciNova, Inc. is a publicly-traded biopharma...
Ultragenyx is a biopharmaceutical company committed to bringing to patients novel ...
Ultragenyx is a biopharmaceutical company commi...
Join the National Investor Network and get the latest information with your interests in mind.